LACTEL 50:50 DL-PLG (B6013-1) Biomedical Acid-Terminated PLGA is a poly(DL-lactide-co-glycolide) copolymer with a 50:50 molar ratio of DL-lactide to glycolide and a terminal carboxylic acid group. The catalogue reference B6013-1 belongs to the acid-terminated biomedical-grade 50:50 DL-PLG family and is supplied as a dry powder for resorbable drug delivery systems, implantable matrices, and porous tissue scaffolds. The DL-lactide component prevents crystallinity; the material is amorphous with a dry-state glass transition typically observed between 40 °C and 50 °C. The 50:50 comonomer balance produces faster ester hydrolysis than 75:25 or 85:15 PLGA grades because the higher glycolide content increases matrix hydrophilicity and water diffusion. Acid termination adds one free carboxylic acid per polymer chain; this functional group is the main chemical distinction from ester-capped 50:50 DL-PLG products and is responsible for higher water uptake, autocatalytic acceleration during degradation, and the ability to conjugate amine-functionalized molecules through carbodiimide coupling. Gel permeation chromatography against polystyrene standards in tetrahydrofuran typically yields a number-average molecular weight of 10,000–25,000 Da for this viscosity range. B6013-1 is most often specified for low-viscosity microsphere and nanoparticle processes where a 0.15–0.25 dL/g inherent viscosity provides a suitable balance between solvent-phase handling and matrix erosion time.

What certificate and lot-release parameters define B6013-1 as an acid-terminated biomedical PLGA?

Lot-release documentation for B6013-1 releases the product against chemical, thermal, and purity parameters that are relevant to biomedical fabrication. The most critical parameter for processing is inherent viscosity, which is determined by dilute-solution viscometry in chloroform and is controlled to 0.15–0.25 dL/g. Monomer ratio is measured by ¹H NMR and is typically controlled within 48–52 mol% lactide and 48–52 mol% glycolide; the terminal acid functionality is quantified by acid–base titration and gives an acid number in the 2–4 mg KOH/g range for a 15,000–25,000 Da number-average molecular weight. Residual lactide and glycolide monomer contents are typically controlled to ≤ 0.5 wt% each. Residual solvent content is tested by headspace gas chromatography against ICH Q3C Class 2 limits for the solvent system used in manufacture. Moisture content is determined by Karl Fischer titration and is typically controlled to ≤ 0.5 wt%. Bacterial endotoxin testing is performed according to USP <85> for parenteral-grade applications, with typical acceptance criteria of ≤ 0.5 EU/mg.

These ranges are typical lot-release criteria for biomedical acid-terminated 50:50 PLGA; purchasing specifications may impose tighter monomer, endotoxin, or molecular-weight limits for specific drug delivery devices. Because molecular weight, acid number, and residual moisture interact to control downstream degradation, changing any one of these parameters without adjusting the others can shift the in vivo erosion window.

Pre-drying of B6013-1 is required before melt processing or after any exposure of the opened foil pouch to ambient humidity. Vacuum drying at 25–35 °C for 24–72 h at −70 kPa or below reduces moisture to ≤ 0.5 wt%; if the powder is not dried, twin-screw processing can lose 10–20% of the starting molecular weight through hydrolysis before the material exits the die. For solvent-based microsphere lines, the polymer is dissolved in dichloromethane or ethyl acetate and dispersed into an aqueous polyvinyl alcohol continuous phase under a rotor-stator mixer operating at 10,000–20,000 rpm; particle size can be driven into the 1–20 µm range by adjusting dispersed-phase viscosity, surfactant concentration, and tip speed. The terminal carboxyl group ionizes above approximately pH 4.5–5.0, and this can reduce encapsulation of cationic drugs when the aqueous phase pH is above the drug isoelectric point; buffering the external phase below the polymer acid dissociation point often improves loading.

Melt extrusion of B6013-1 is feasible on a co-rotating twin-screw extruder with an L/D ratio from 25:1 to 40:1, but the processing window is narrow. Barrel temperatures are typically set from 120 °C at the feed section to 160 °C at the die; residence time should be kept below 5 min because thermal degradation of the ester backbone accelerates sharply above 180 °C. Flood-fed single-screw extrusion is generally not recommended because the material lacks crystallinity and exhibits melt strength limitations. Injection molding of small resorbable implants has been reported when mold temperatures are held below the wet glass transition of the degrading polymer and gate design minimizes shear heating.

For nanoprecipitation or continuous-flow nanoprecipitation processes, B6013-1 is dissolved at 1–5 wt% in a water-miscible solvent such as acetone and mixed with an aqueous stabilizer phase at controlled flow rates. The resulting particle size is strongly influenced by polymer concentration and the anti-solvent ratio; lot-to-lot molecular weight and acid number changes can shift mean particle diameter by 10–30% if the solvent-to-antisolvent ratio is not compensated. Continuous-flow cells with a T-junction or confined impinging jet mixer are used to raise production throughput while maintaining laminar mixing; this equipment choice reduces batch-to-batch variation relative to magnetic stirring in open beakers. Organic-solvent removal is performed by rotary evaporation or tangential flow filtration, and residual solvent is measured by headspace GC to confirm compliance with ICH Q3C before lyophilization.

Degradation kinetics and the autocatalytic influence of the terminal carboxyl group

Degradation of B6013-1 proceeds by bulk ester hydrolysis, not surface erosion. In phosphate-buffered saline at pH 7.4 and 37 °C, 50:50 PLGA grades with 0.15–0.25 dL/g inherent viscosity typically exhibit a mass-loss half-time of 4–6 weeks under static immersion. The free terminal carboxyl group increases water uptake and provides an acidic local environment that accelerates the autocatalytic phase of hydrolysis. Published mass-loss data specific to B6013-1 under the exact immersion conditions of ISO 13781:2017 are limited; the stated range should be considered a comparator for a 50:50 acid-terminated PLGA of equivalent molecular weight rather than a device-specific specification. Molecular weight declines before mass loss becomes measurable, and the polydispersity index can increase from about 1.5 to above 2.0 during the lag phase. As the number-average molecular weight falls below approximately 5,000 Da, the glass transition typically drops below 37 °C, causing the matrix to soften and swell in vivo. The released monomers, lactic acid and glycolic acid, enter normal metabolic pathways, but the local pH drop within a large implant can be 1–2 pH units lower than the surrounding tissue and must be considered in device design.

In drug delivery characterization, in vitro release is typically measured using USP Apparatus 4 flow-through cells or USP Apparatus 2 paddle methods with sink conditions. For acid-terminated 50:50 PLGA microspheres, the early release phase can be governed by surface-associated drug and particle porosity, while the later phase follows polymer erosion. Reports on comparable low-IV PLGA grades indicate that lowering residual monomer content below 0.5 wt% and narrowing the particle size distribution can reduce run-to-run release variability from ±10–15% to below ±5% at equivalent sampling points. Published data for this specific catalogue grade in large-animal pharmacokinetic studies are limited; release profiles should be qualified by in vitro–in vivo correlation using the actual device geometry.

When B6013-1 replaces an ester-capped 50:50 DL-PLG in microsphere and implant prototyping

Substitution of B6013-1 for an ester-capped 50:50 PLGA changes the formulation in three main areas. The free carboxyl group increases hydrophilicity and can bind basic or cationic drugs by electrostatic interaction; this often lowers the 24 h in vitro burst release for cationic peptides or amine-containing small molecules, but may increase burst for neutral hydrophobic drugs because water ingress is faster. The terminal acid also provides a direct conjugation site for amine-functionalized poly(ethylene glycol), targeting ligands, or fluorophores through N-hydroxysuccinimide/carbodiimide chemistry; ester-capped analogues require chain-end deprotection or alternative coupling strategies. The acid-terminated grade may shorten the in vitro degradation lag phase by 1–3 weeks compared with an ester-capped product of the same comonomer ratio and molecular weight. This shift can be advantageous when the clinical release window requires earlier matrix erosion, but it also increases the sensitivity of the lot to moisture during storage and to terminal sterilization dose.

These comparative values are representative ranges from published in vitro studies on 50:50 PLGA with 0.15–0.25 dL/g inherent viscosity and should not replace lot-specific validation for B6013-1 device release. Compared with 75:25 DL-PLG, B6013-1 absorbs water more rapidly and loses mass earlier; compared with 85:15 poly(DL-lactide-co-glycolide), the 50:50 ratio may reduce the in vitro degradation half-life by more than half under the same incubation conditions. The tradeoff is a narrower processing window and higher moisture sensitivity.

Biomedical use of B6013-1 is supported by qualification against ISO 10993-1:2018 for biological evaluation of the finished device, ISO 13781:2017 for lactide/glycolide copolymer implants, and ISO 13485:2016 for manufacture of medical device materials. Gamma irradiation can reduce molecular weight by 5–20% depending on absorbed dose, oxygen exposure, and moisture; the initial intrinsic viscosity must therefore be selected to retain functionality after terminal sterilization. The product should be stored at −20 °C in sealed, desiccated, inert-gas-purged packaging. Repeated warming to ambient conditions should be minimized. The free carboxyl group is reactive with amine-functionalized additives and active pharmaceutical ingredients; melt-phase compounding with high loadings of basic drugs may cause condensation reactions, color formation, and viscosity drift. Alkaline processing media above pH 8.0 should be avoided because rapid ester hydrolysis occurs. These operational boundaries define the practical envelope for formulation and manufacture with B6013-1.